Project Grant R21AI185243
- This Project Grant award of $426,938.00 from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to develop a simple and inexpensive mouse model of chronic Mycobacterium abscessus lung disease. The principal investigator at The Johns Hopkins University will verify the reproducibility of a proof-of-concept model using additional M. abscessus isolates and test whether the model can faithfully reproduce...
- This $228,435 federal Project Grant was awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) on January 16, 2025. The grant supports research to uncover the mechanisms enabling the cross-species jumps of viruses, such as the SARS-CoV-2 pandemic and monkeypox (mpox) epidemic, focusing on the Myxoma virus (MYXV) as a model system. The research aims to study the evolution and host adaptation of MYXV,...
- This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), is providing $402,860 to the University of Cincinnati to develop a molecular toolbox for the fungal pathogen Pneumocystis jirovecii (PJ). The primary goal is to establish a transformation system using CRISPR/Cas9 gene editing and plasmid-mediated approaches to enable functional studies on the biology and pathogenesis of...
- This Project Grant awarded by the National Institutes of Health (NIH) Office of Research Infrastructure Programs (CFDA 93.351) provides $844,954 to New York University School of Medicine to develop "Genomically Rewritten and Tailored Humanized Mouse Models for Various Organ Disorders." The project leverages advanced DNA synthesis and editing capabilities to create genetically engineered mouse models (GREAT-GEMMs) that accurately represent specific human disease phenotypes. These...
- This Project Grant award of $413,860 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) aims to investigate the interactions between non-tuberculous mycobacteria (NTM) infections, specifically Mycobacterium abscessus (MAB), and the onset/flares of systemic lupus erythematosus (SLE). Using preclinical mouse models and an ex vivo model with alveolar-like macrophages, the researchers will examine the...
- This Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), will provide $423,500.00 to Nova Southeastern University, Inc. to develop a humanized mouse model of periodontitis. The goal is to investigate the potential pathogenic role of the protein Semaphorin 4D expressed by human osteoclasts in the progression of periodontal disease. This advanced mouse model will allow researchers to...
- The University of Rhode Island (URI) Research Office is receiving a $2,727,001 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Drug Abuse and Addiction Research Programs (CFDA 93.279). The grant will fund research to validate a rabbit model of cerebral palsy-induced pain. Key components include: Determining the face validity of the rabbit hypoxia-ischemia model to assess musculoskeletal, nociplastic, and neuropathic pain phenotypes...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $453,750 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), for research on Pseudomonas aeruginosa infections and neutrophil swarming behavior. The funding will support a 2-year project to develop an ex vivo model to study how neutrophils coordinate to surround and neutralize large bacterial...
- This federal Project Grant award from the National Center for Advancing Translational Sciences (NCATS), CFDA 93.350, provides $489,500 to The Children's Hospital of Philadelphia (CHOP) to conduct research on the use of the compound Repsox for prophylactic intervention in Familial Platelet Disorder with associated Myeloid Malignancy (FPDMM) due to RUNX1 haploinsufficiency. The research aims to examine the effects of Repsox on RUNX1 expression, activity, and isoform usage in FPDMM hematopoietic...
- This $430,760 Project Grant was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), which administers the Allergy and Infectious Diseases Research program (CFDA 93.855), to the University of Pittsburgh. The grant supports research to train neutrophils, a type of white blood cell, to defend against a lethal bacterial infection of the lung caused by Pseudomonas aeruginosa. The key objectives are to establish a strategy to improve the host's immune defense against this...
DEVELOPMENT OF A RABBIT MODEL FOR MYELOPEROXIDASE DEFICIENCY - ABSTRACT MYELOPEROXIDASE (MPO) IS A UNIQUE PEROXIDASE, PREDOMINANTLY EXPRESSED IN NEUTROPHILS AND STORED IN THEIR AZUROPHILIC GRANULES, AND ACCOUNTS FOR ~5% OF THE TOTAL CELL PROTEIN. AMONG ALL THE DISCOVERED PEROXIDASES, MPO IS THE ONLY ONE THAT CATALYZES TWO-ELECTRON OXIDATION OF CHLORIDE ANION TO PRODUCE HYPOCHLOROUS ACID (HOCL) IN THE PRESENCE OF H2O2 DERIVED FROM THE NADPH OXIDASE. CLINICAL VALIDATION OF THE IMPORTANCE OF THE OXIDANT-DEPENDENT SYSTEM FOR OPTIMAL HOST DEFENSE RESTS IN PART ON THE SEVERE AND OFTEN FATAL INFECTIONS SEEN IN PATIENTS WITH CHRONIC GRANULOMATOUS DISEASE (CGD), AN INHERITED DISORDER WITH NON-FUNCTIONAL PHAGOCYTE NADPH OXIDASE. INTRIGUINGLY, INDIVIDUALS WITH INHERITED MPO DEFICIENCY DEVELOP A NARROW SET OF INFECTIONS, LARGELY BY FUNGI. THE MOLECULAR BASIS FOR SUCH A PHENOTYPE OF MPO DEFICIENCY IS NOT CLEARLY KNOWN, BUT LIKELY REFLECTS ACTIONS BY UNCHARACTERIZED ANTIMICROBIAL ACTIVITIES THAT MAY LIE IN RESERVE BUT ARE RECRUITED UNDER SEVERE STRESS. CLINICAL DATA FURTHER SUGGEST THAT MPO CONTRIBUTES TO TISSUE DAMAGE AND INFLAMMATION, AND IS INVOLVED IN THE PATHOGENESIS OF MANY INFLAMMATORY DISEASES INCLUDING CARDIOVASCULAR DISEASES, KIDNEY DISEASES, PULMONARY INFLAMMATION, RHEUMATOID ARTHRITIS, SKIN INFLAMMATION, AND NEURONAL DISEASES. IN SPITE OF THE LONG-OBSERVED CLINICAL ASSOCIATION BETWEEN MPO AND INFLAMMATION, THE EXACT ROLE OF MPO IN THE ONSET AND PROGRESSION OF INFLAMMATORY DISEASES REMAINS LARGELY ELUSIVE. ONE OF THE MAJOR OBSTACLES IMPEDING PROGRESS IN UNDERSTANDING THE CONTRIBUTION OF MPO TO HOST DEFENSE AND TO INFLAMMATION BIOLOGY IS THE LACK OF A FAITHFUL ANIMAL MODEL. WIDELY USED IN THE FIELD, MPO-KNOCKOUT (MPO-KO) MICE FAIL IN MANY SETTINGS TO RECAPITULATE MPO-ASSOCIATED HUMAN DISEASES, AS DATA OBTAINED OFTEN CONTRADICT THOSE SEEN IN HUMANS. TO MEET THE URGENT NEED FOR AN ACCURATE FAITHFUL ANIMAL MODEL, WE HAVE PRODUCED AN MPO-KO RABBIT MODEL USING CRIPSR/CAS9 GENE EDITING TECHNOLOGY. DUE TO MANY SIMILARITIES BETWEEN THE RABBIT AND HUMAN IMMUNE SYSTEMS, WE EXPECT THIS NOVEL MODEL TO BE OF GREAT VALUE IN STUDYING CLINICAL MPO DEFICIENCY. OUR OVERARCHING HYPOTHESIS IS THAT RABBIT MPO DEFICIENCY REPLICATES HUMAN MPO DEFICIENCY IN BOTH INFECTION AND INFLAMMATION DISEASES, PROVIDING A VALUABLE TOOL FOR NOVEL BASIC DISCOVERY AND THERAPEUTIC DEVELOPMENT. THERE ARE TWO SPECIFIC AIMS IN THIS R21 PROPOSAL: 1) TO DETERMINE IF RABBIT MPO DEFICIENCY REPRODUCES HUMAN MPO DEFICIENCY IN INFECTION; 2) TO DISCOVER IF RABBIT MPO DEFICIENCY RECAPITULATES HUMAN MPO DEFICIENCY IN INFLAMMATION. COMPLETION OF THIS RESEARCH WILL ESTABLISH A LARGER ANIMAL MODEL FOR HUMAN MPO DEFICIENCY FOR BASIC RESEARCH AND THERAPEUTIC DEVELOPMENT, WHICH IS EXPECTED TO GREATLY ADVANCE OUR UNDERSTANDING OF THE BIOLOGY OF MPO AND THE MPO- RELATED DISEASES, AND TO FACILITATE THE SEARCH FOR EFFECTIVE INTERVENTIONS FOR THESE CONDITIONS.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $187.5k | 3/21/25 | ||
| Not listed | $22.5k | 9/11/24 | ||
| Not listed | $22.5k | 9/11/24 | ||
| Not listed | $202.5k | 6/27/24 | ||
| Not listed | $202.5k | 6/27/24 |